UGRO CAPITAL LIMITED PUBLIC ISSUE OF SECURED, RATED, LISTED, REDEEMABLE, NON-CONVERTIBLE DEBENTURES (SECURED NCDS) OPENS TODAY EFFECTIVE ANNUALIZED YIELD UP TO 11.01% PER ANNUM*

▴ UGRO Capital Limited
The NCDs are proposed to be listed on BSE and NSE (collectively, “Stock Exchanges”). Allotments, in consultation with the National Stock Exchange of India Limited (the “Designated Stock Exchange”), shall be made on the basis of the date of upload of the application on the electronic book of the Stock Exchanges in accordance with the SEBI Master Circular. However, on the date of oversubscription and thereafter, the allotment shall be made to the applicants on a proportionate basis.
 
  • Secured NCDs of face value (“Face Value”) of Rs. 1,000 each.
  • The Issue is for an amount of ? 10,000 lakh (“Base Issue Size”) with an option to retain oversubscription up to     ? 10,000 lakh (“Green Shoe Option”) aggregating up to ? 20,000 lakh.
  • Rated as “IND A+/Stable” by India Ratings and Research Private Limited.
  • Effective annualized yield up to 11.01% p.a*.        
  • The Issue opens on Thursday, April 3, 2025 and closes on Monday, April 21, 2025 with an option of early closure subject to compliance with Regulation 33A of the SEBI NCS Regulations**.
 
Hyderabad, April 3, 2025: UGRO Capital Limited, an NBFC focused on MSME lending, today announced the issue of secured, rated, listed, redeemable, non-convertible debentures of the face value of ? 1,000 each. The Issue has a base issue size of ? 10,000 lakhs with an option to retain oversubscription up to ? 10,000 lakh, aggregating up to ? 20,000 lakh. The Issue opens on Thursday, April 3, 2025 and closes on Monday, April 21, 2025 with an option of early closure subject to compliance with Regulation 33A of the SEBI NCS Regulations.
The NCDs are proposed to be listed on the Stock Exchanges and NSE is the Designated Stock Exchange for the Issue. The NCDs have been rated “IND A+/Stable” by India Ratings and Research Private Limited. Securities with this rating are considered to have adequate degree of safety regarding timely servicing of financial obligations.
Tipsons Consultancy Services Private Limited is the sole lead manager to the issue and MUFG Intime India Private Limited (formerly known as Link Intime India Private Limited) is the Registrar to the Issue and MITCON Credentia Trusteeship Services Limited is the debenture trustee to the Issue.
This issue has tenor of 18 months, 24 months, 30 months, and 42 months for secured NCDs. Effective yield (% per annum) for NCD holders in all Categories ranges from 10.47% to 11.01%. Redemption Amount (? / NCD) on maturity for NCD holders in all Categories range is ? 1000.
At least 75% of the Net proceeds of the Issue shall be utilized for the purpose of onward lending and financing business of the company in ordinary course of business (including for repayment / refinance of existing debts of the Company) and Not exceeding 25% shall be used for general corporate purposes.
As on December 31, 2024 UGRO Capital’s CRAR, in accordance with the Limited Reviewed Financial Results was at 21.52%. Its AUM has grown from ?2,96,890.60 lakh as of March 31, 2022, to ?9,04,705.74 lakh as of March 31, 2024. As of December 31, 2024, the Company was operating from 23 prime branches and 201 Emerging Market branches with an AUM of ? 11,06,656.73 lakh and catering more than 1,35,000 lakh customers. Across the offered products, as on December 31, 2024, the average ticket size stood at ? 11.37 lakh and the portfolio yield stood at 16.65%.
The specified terms of the NCDs Issue are set out below:
Series
I
II
III
IV
V*
Frequency of Interest Payment
Monthly
Annually
Monthly
Monthly
Monthly
Minimum Application
? 10,000 (10 NCDs) across all Series
Face Value/ Issue Price of NCDs (?/ NCD)
?1000 (1 NCD)
In Multiples of thereafter (?)
? 1000 (1 NCD)
Tenor
18 Months
18 Months
24 Months
30 Months
42 Months
Coupon (% per annum) for NCD Holders in Category I, II, III & IV
10.00%
10.39%
10.15%
10.25%
10.50%
Effective Yield (per annum) for NCD Holders in Category I, II, III & IV
10.47%
10.47%
10.64%
10.75%
11.01%
Mode of Interest Payment
Through various modes available
Amount (? / NCD) on Maturity for NCD Holders in Category I, II, III & IV
?1000 (1 NCD)
Maturity / Redemption Date (Months from the Deemed Date of Allotment)
Date occurring on expiry of 18 (Eighteen) months from the Deemed Date of Allotment
Date occurring on expiry of 18 (Eighteen) months from the Deemed Date of Allotment
Date occurring on expiry of 24 (Twenty Four) months from the Deemed Date of Allotment
Date occurring on expiry of 30 (Thirty) months from the Deemed Date of Allotment
Date occurring on expiry of 42 (Forty Two) months from the Deemed Date of Allotment
Put and Call Option
NA
NA
NA
NA
NA
* Our Company shall allocate and allot Series V NCDs wherein the Applicants have not indicated the choice of the relevant NCD Series.
Tags : #

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026